BUZZ-Fulcrum Therapeutics 因肌肉失调药物在后期研究中失败而受挫

Reuters09-12

((自动化翻译由路透提供，请见免责声明 ))

9月12日 - ** 药物开发商Fulcrum Therapeutics 股价盘前暴跌70.62%，至2.60美元

** 该公司称， (link)，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标

** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者(FSHD)，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。

** Adds 将暂停未来 losmapimod 的开发

** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大

** 截至上一交易日收盘，股价年累计上涨约 31

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2466276769?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-12 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466276769","market":"us","top_or_hot":-1,"title":"BUZZ-Fulcrum Therapeutics 因肌肉失调药物在后期研究中失败而受挫","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    9月12日 - ** 药物开发商<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a>   股价盘前暴跌70.62%，至2.60美元</p><p>** 该公司称， (link)，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标</p><p>** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者(FSHD)，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。</p><p>** Adds 将暂停未来 losmapimod 的开发</p><p>** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大</p><p>** 截至上一交易日收盘，股价年累计上涨约 31 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Fulcrum Therapeutics 因肌肉失调药物在后期研究中失败而受挫</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Fulcrum Therapeutics 因肌肉失调药物在后期研究中失败而受挫\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 19:54 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    9月12日 - ** 药物开发商Fulcrum Therapeutics   股价盘前暴跌70.62%，至2.60美元** 该公司称， (link)，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者(FSHD)，这些患者在48周的时间里...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2466276769","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466276769","pubTimestamp":1726142090,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    9月12日 - ** 药物开发商Fulcrum Therapeutics   股价盘前暴跌70.62%，至2.60美元** 该公司称， ，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。** Adds 将暂停未来 losmapimod 的开发** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大** 截至上一交易日收盘，股价年累计上涨约 31","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"FULC":"Fulcrum Therapeutics","LENZ":"Therapeutics","BK4007":"制药","BK4139":"生物科技"},"translate_title":"BUZZ-Fulcrum Therapeutics Frustrated by Muscle Disorders Drug Failing in Late-Stage Study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1,"LENZ":1},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    9月12日 - ** 药物开发商Fulcrum Therapeutics   股价盘前暴跌70.62%，至2.60美元** 该公司称， (link)，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者(FSHD)，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。** Adds 将暂停未来 losmapimod 的开发** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大** 截至上一交易日收盘，股价年累计上涨约 31","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466276769"}